Release Details

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

PTC Therapeutics to Present at the Leerink Partners Rare Disease Roundtable

September 24, 2014

SOUTH PLAINFIELD, N.J., Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1st at 8:25 am ET at Le Parker Meridien in New York City.

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The webcast will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation slide deck is available at the same website location.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

Logo - http://photos.prnewswire.com/prnh/20010919/PTCLOGO

SOURCE PTC Therapeutics, Inc.

 

 

News Provided by Acquire Media